South Korea
· Delayed Price · Currency is KRW Bridge Biotherapeutics Statistics
Total Valuation
Bridge Biotherapeutics has a market cap or net worth of KRW 182.55 billion. The enterprise value is 179.23 billion.
| Market Cap | 182.55B |
| Enterprise Value | 179.23B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Bridge Biotherapeutics has 45.81 million shares outstanding. The number of shares has increased by 21.53% in one year.
| Shares Outstanding | 45.81M |
| Shares Change (YoY) | +21.53% |
| Shares Change (QoQ) | +4.37% |
| Owned by Insiders (%) | 11.75% |
| Owned by Institutions (%) | 8.89% |
| Float | 39.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -332,083,333.33 |
| PB Ratio | 9.88 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.41 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.52 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 25.00.
| Current Ratio | 1.57 |
| Quick Ratio | 1.51 |
| Debt / Equity | 25.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.11 |
| Interest Coverage | -178.47 |
Financial Efficiency
Return on equity (ROE) is -143.32% and return on invested capital (ROIC) is -67.36%.
| Return on Equity (ROE) | -143.32% |
| Return on Assets (ROA) | -58.54% |
| Return on Capital (ROIC) | -67.36% |
| Revenue Per Employee | -10 |
| Profits Per Employee | -946.05M |
| Employee Count | 35 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.33% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -18.33% |
| 50-Day Moving Average | 2,717.58 |
| 200-Day Moving Average | 2,600.18 |
| Relative Strength Index (RSI) | 60.42 |
| Average Volume (20 Days) | 2,803,470 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bridge Biotherapeutics had revenue of KRW -340 and -33.11 billion in losses. Loss per share was -1,243.82.
| Revenue | -340 |
| Gross Profit | -83.23M |
| Operating Income | -30.46B |
| Pretax Income | -33.42B |
| Net Income | -33.11B |
| EBITDA | -29.01B |
| EBIT | -30.46B |
| Loss Per Share | -1,243.82 |
Balance Sheet
The company has 9.14 billion in cash and 3.14 billion in debt, giving a net cash position of 6.00 billion or 130.96 per share.
| Cash & Cash Equivalents | 9.14B |
| Total Debt | 3.14B |
| Net Cash | 6.00B |
| Net Cash Per Share | 130.96 |
| Equity (Book Value) | 12.54B |
| Book Value Per Share | 403.30 |
| Working Capital | 3.50B |
Cash Flow
In the last 12 months, operating cash flow was -27.37 billion and capital expenditures -121.47 million, giving a free cash flow of -27.49 billion.
| Operating Cash Flow | -27.37B |
| Capital Expenditures | -121.47M |
| Free Cash Flow | -27.49B |
| FCF Per Share | -600.12 |
Margins
| Gross Margin | n/a |
| Operating Margin | 8,957,455,791.18% |
| Pretax Margin | 9,828,902,652.94% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | 8,085,756,600.00% |
Dividends & Yields
Bridge Biotherapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.53% |
| Shareholder Yield | -21.53% |
| Earnings Yield | -31.21% |
| FCF Yield | -15.06% |
Stock Splits
The last stock split was on July 29, 2024. It was a forward split with a ratio of 1.2.
| Last Split Date | Jul 29, 2024 |
| Split Type | Forward |
| Split Ratio | 1.2 |